Philippe Ledru - Aptose Biosciences Senior Officer
| APTO Stock | USD 0.18 0.01 5.26% |
Executive
Philippe Ledru is Senior Officer of Aptose Biosciences
| Age | 56 |
| Address | 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 |
| Phone | 647 479 9828 |
| Web | https://www.aptose.com |
Aptose Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.3629) % which means that it has lost $1.3629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9413) %, meaning that it created substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aptose Biosciences' Return On Capital Employed is very stable compared to the past year. As of the 3rd of December 2024, Return On Equity is likely to grow to 18.53, though Return On Tangible Assets are likely to grow to (3.75). At this time, Aptose Biosciences' Non Current Assets Total are very stable compared to the past year. As of the 3rd of December 2024, Other Current Assets is likely to grow to about 2.8 M, while Total Assets are likely to drop about 12.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Clement Monteil | Virax Biolabs Group | N/A | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| Alfonso MD | Foghorn Therapeutics | 53 | |
| James Wang | Virax Biolabs Group | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Mike Rhee | Senti Biosciences | N/A | |
| Dee Dragon | Senti Biosciences | N/A | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| Thomas Chung | Senti Biosciences | N/A | |
| MS MD | Candel Therapeutics | 55 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| Kristian MBA | Foghorn Therapeutics | 48 | |
| Michael JD | Foghorn Therapeutics | 59 | |
| Khullani JD | Cardio Diagnostics Holdings | 40 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
Management Performance
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 |
Aptose Biosciences Leadership Team
Elected by the shareholders, the Aptose Biosciences' board of directors comprises two types of representatives: Aptose Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptose. The board's role is to monitor Aptose Biosciences' management team and ensure that shareholders' interests are well served. Aptose Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptose Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philippe Ledru, Senior Officer | ||
| Fletcher Payne, CFO, VP | ||
| Janet CA, VP Fin | ||
| Rafael MD, Senior Officer | ||
| Roger BSc, Vice Operations | ||
| Marc Wiles, Senior Affairs | ||
| Brooks MBA, VP Controller | ||
| William Rice, Chairman, CEO and Pres |
Aptose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptose Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | 3.11 M | ||||
| Shares Outstanding | 59.52 M | ||||
| Shares Owned By Insiders | 16.38 % | ||||
| Shares Owned By Institutions | 16.68 % | ||||
| Number Of Shares Shorted | 120.72 K | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 67.84 X | ||||
| EBITDA | (52.27 M) |
Pair Trading with Aptose Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptose Stock
Moving against Aptose Stock
| 0.71 | DMAC | DiaMedica Therapeutics Downward Rally | PairCorr |
| 0.71 | VCYT | Veracyte | PairCorr |
| 0.71 | DRTS | Alpha Tau Medical Trending | PairCorr |
| 0.66 | VCEL | Vericel Corp Ord | PairCorr |
| 0.6 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.